Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.48 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.48 |
| ▸ | EIF4E | P06730 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | KIT | P10721 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.39 |
| ▸ | IDH1 | O75874 | 3/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24956536 | 0.89 | MET (0.49) | JAK2MKNK1MKNK2NTRK1ABL1 | |
| SCHEMBL24958704 | 0.82 | PIM1 (0.54) | JAK2MKNK1MKNK2EIF4ENTRK1 | |
| SCHEMBL24958712 | 0.80 | BRD4 (0.45) | JAK2MKNK1MKNK2EIF4ENTRK1 | |
| SCHEMBL24958695 | 0.79 | DPP4 (0.37) | BRD4METCREBBP | |
| SCHEMBL17806593 | 0.78 | KCNH2 (0.49) | IDH1 | |
| SCHEMBL24958928 | 0.72 | PIK3CD (0.49) | CREBBP | |
| SCHEMBL24958943 | 0.72 | IRAK4 (0.49) | JAK2MKNK1NTRK1PIM1ABL1 | |
| SCHEMBL24958864 | 0.71 | BRD4 (0.40) | JAK2MKNK1MKNK2NTRK1BRD4 | |
| SCHEMBL24956537 | 0.71 | S1PR1 (0.48) | JAK2PIM1ABL1JAK1JAK3 | |
| SCHEMBL24958866 | 0.71 | BRD4 (0.40) | JAK2MKNK1MKNK2NTRK1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | JAK2 1740/4885MKNK1 804/4885MKNK2 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.